Txr1: An important factor in oxaliplatin resistance in gastric cancer

Medical Oncology

Volumn 31, Issue 2, 2014, Pages

  Bi, Jingtao ^a   Bai, Zhigang ^b   Ma, Xuemei ^b   Song, Jianning ^b   Guo, Yantong ^a   Zhao, Jingming ^a   Yi, Xin ^a   Han, Shiwei ^b   Zhang, Zhongtao ^b  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Chemotherapy resistance; Oxaliplatin; Sirna; Txr1

Indexed keywords

MESSENGER RNA; OXALIPLATIN; PROTEIN; THROMBOSPONDIN 1; TXR1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PLATINUM COMPLEX; PRR13 PROTEIN, HUMAN; REPRESSOR PROTEIN; SMALL INTERFERING RNA; SPZ1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE LOCATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; VERY ELDERLY; WESTERN BLOTTING; ADENOCARCINOMA; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL CULTURE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84890423553     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0807-1     Document Type: Article

References (17)

1. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18(3): 504-9.
2. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33(4):315-24.
3. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291-5.
4. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to- mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12(14 Pt1):4147-53.
5. Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC, Liu JF, Yeh SC, Tsai FY, Hsieh HP, Chang JY. Combinedmodalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer. 2007;97(3):334-44.
6. Lih CJ, Wei W, Cohen SN. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to Taxanes. Genes Dev. 2006;20(15):2082-95.
7. Bai ZG, Qu X, Han W, Ma XM, Zhao XM, Zhang ZT. Expression of taxol resistance gene 1 correlates with gastric cancer patient clinical outcome and induces taxol resistance. Mol Med Rep. 2010;3(6):1071-8.
8. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V, Souglakos J. Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxelgemcitabine regimen. Clin Cancer Res. 2009;15(11):3827-33.
9. Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs. 2010;21(4):381-8.
10. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzen F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase three open-label, randomised controlled trial. Lancet. 2012;379(9813): 315-21.
11. Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, Mann W, Petersen I, Heinzel T, Stauber RH. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007;21(1):207-16.
12. Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 2007;109(2):228-38.
13. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther. 2007;7(10):1369-78.
14. Mateo V, Brown EJ, Biron G, Rubio M, Fischer A, Deist FL, Sarfati M. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood. 2002;100(8):2882-90.
15. Saumet A, Slimane MB, Lanotte M, Lawler J, Dubernard V. Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/v3 in promyelocytic leukemia NB4 cells. Blood. 2005;106(2):658-67.
16. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase independent apoptosis in Survivin targeted melanoma cells. Oncogene. 2004;23(1):39-48.
17. Pavlyukov Marat S, Antipova Nadezhda V, Balashova Maria V, Vinogradova Tatjana V, Kopantzev Evgenij P, Shakhparonov Mihail I. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem. 2011;286(26):23296-307.